...

首页> 外文期刊>BJU International >THE COST-EFFECTIVENESS OF SOLIFENACIN VS FESOTERODINE, OXYBUTYNIN IMMEDIATE-RELEASE, PROPIVERINE, TOLTERODINE EXTENDED-RELEASE AND TOLTERODINE IMMEDIATE-RELEASE IN THE TREATMENT OF PATIENTS WITH OVERACTIVE BLADDER IN THE UK NATIONAL HEALTH SERVICE

【24h】

THE COST-EFFECTIVENESS OF SOLIFENACIN VS FESOTERODINE, OXYBUTYNIN IMMEDIATE-RELEASE, PROPIVERINE, TOLTERODINE EXTENDED-RELEASE AND TOLTERODINE IMMEDIATE-RELEASE IN THE TREATMENT OF PATIENTS WITH OVERACTIVE BLADDER IN THE UK NATIONAL HEALTH SERVICE

机译：索非那宁比索非丁定，奥昔布宁立即释放，异丙肾上腺素，托罗替丁延长释放和托罗替丁立即释放在英国国家卫生服务部门活动过度的患者中的成本效益

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

No abstract is available for this article.

机译：本文没有摘要。

著录项

来源
《BJU International》 |2010年第4期|p.586|共1页
作者
Juliet L. Warner;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
专利

1. The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service [J] . Linda Cardozo Andrew Thorpe Juliet Warner, Linda Cardozo Andrew Thorpe Juliet Warner BJU International . 2010,第4期

机译：在英国国家卫生服务局治疗索非那定与非索罗定，奥昔布宁立即释放，丙氧维林，托特罗定延长释放和托特罗定立即释放在膀胱过度活动症患者中的成本效益
2. The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service. [J] . Cardozo L, Thorpe A, Warner J, BJU international . 2010,第4期

机译：在英国国家卫生服务部治疗膀胱过度活动症患者中，索非那新与非索罗定，奥昔布宁速释，丙泊灵，托特罗定缓释和托特罗定即释的成本效益比较。
3. The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service. [J] . Warner JL BJU international . 2010,第4期

机译：在英国国家卫生服务部治疗膀胱过度活动症患者中，索非那新与非索罗定，奥昔布宁速释，丙泊灵，托特罗定缓释和托特罗定即释的成本效益比较。
4. Health economics perspective of fesoterodine tolterodine or solifenacin as first-time therapy for overactive bladder syndrome in the primary care setting in Spain [O] . Antoni Sicras-Mainar, Javier Rejas, Ruth Navarro-Artieda, 2013

机译：非索罗定托特罗定或索非那新在西班牙初级保健机构中作为膀胱过动症综合治疗的首次疗法的健康经济学视角
5. PUK10 Cost-Effectiveness Analysis of Solifenacin Versus Oxybutynin Immediate-Release in the Treatment of Patients with Overactive Bladder in the United Kingdom [O] . Hart W.M., Munro V., Retsa P. 2011

机译：英国索非那新与奥昔布宁立即释放治疗膀胱过度活动症患者的PUK10成本-效果分析

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号